Pharma Mar, S.A.: Business Overview, Financials & Competitive Analysis
Pharma Mar, S.A. scores 8/10 on the AskCyborg Cyborg Score (Strong). Differentiated marine biopharmaceutical with 37.5% R&D success rate and portfolio of three marketed oncology drugs supported by intense innovation spending. Pharma Mar invests 61.3% of revenues in R&D—nearly triple industry peers and well above the global pharmaceutical average of 30%. The company commands a rare marine-derived compound platform with.
What is Pharma Mar, S.A.'s industry? Pharma Mar, S.A. (pharmamar.com) operates in Biopharmaceuticals & Oncology. AskCyborg classifies Pharma Mar, S.A. under Biopharmaceuticals & Oncology in its company registry.
Pharma Mar is a global leader in the research, development, and commercialization of marine-derived oncology therapies. The company discovers new anti-tumour molecules of marine origin and markets key products includi...
Cyborg Score thesis
Differentiated marine biopharmaceutical with 37.5% R&D success rate and portfolio of three marketed oncology drugs supported by...
Read the full analyst-debate transcript →Get the Latest Pharma Mar, S.A. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePharma Mar, S.A. Overview
Pro stress-test →Pharma Mar is a global leader in the research, development, and commercialization of marine-derived oncology therapies. The company discovers new anti-tumour molecules of marine origin and markets key products including Yondelis (trabectedin) for soft tissue sarcoma and ovarian cancer, Aplidin (plitidepsin) for multiple myeloma, and Zepzelca (lurbinectedin) for small cell lung cancer. The company allocates 61.3% of its revenues to R&D, nearly three times higher than the next Spanish company and consolidates over a decade of leadership in this classification.
Strategic Profile
Pro stress-test →Pharma Mar operates through Oncology and RNA Interference segments and was incorporated in 1986, based in Madrid, Spain. The company has achieved a 37.5% success rate in its investigations, far exceeding the 10.8% industry average, with eight compounds reaching clinical trials and three approved. The company operates through subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the US.
Competitive Landscape
Pro stress-test →The company targets the global oncology market with focus on the world's main oncology markets. Pharma Mar competes with large-cap pharma players like Eli Lilly, Merck, and Bristol Myers Squibb in oncology, as well as smaller biotech firms specializing in rare cancers and RNA interference therapeutics. The marine-derived platform and exceptional clinical success rate provide differentiation, though scale and commercialization capabilities lag major competitors.
Industry Context
Pharma Mar, S.A. operates in Biopharmaceuticals & Oncology.
Key facts
Founded: 1986 · Headquarters: Madrid, Spain · Employees: 500 · Revenue: $189.2M · Market cap: $1.7B